Karup Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 18-07-2024
- Paid Up Capital ₹ 0.10 M
as on 18-07-2024
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.05 Cr
as on 18-07-2024
- Satisfied Charges ₹ 2.00 M
as on 18-07-2024
- Revenue 15.16%
(FY 2023)
- Profit 13.05%
(FY 2023)
- Ebitda 448.59%
(FY 2023)
- Net Worth 36.62%
(FY 2023)
- Total Assets 429.91%
(FY 2023)
About Karup Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.05 Cr. The company has closed loans amounting to ₹2.00 M, as per Ministry of Corporate Affairs (MCA) records.
Radha Varigonda, Uma Varigonda, Kiranteja Varigonda, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24220TG2005PTC046181
- Company No.
046181
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 May 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Karup Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pavan Varigonda  | Director | 04-Mar-2022 | Current |
| Radha Varigonda | Director | 10-May-2005 | Current |
| Uma Varigonda | Director | 10-May-2005 | Current |
| Kiranteja Varigonda | Director | 23-Nov-2020 | Current |
| Varigonda Veekshitha | Director | 23-Nov-2020 | Current |
Financial Performance of Karup Pharma.
Karup Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.16% increase. The company also saw a substantial improvement in profitability, with a 13.05% increase in profit. The company's net worth Soared by an impressive increase of 36.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Karup Pharma?
In 2023, Karup Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 03 Jun 2022 | ₹2.05 Cr | Open |
Syndicate Bank Creation Date: 10 Mar 2006 | ₹2.00 M | Satisfied |
How Many Employees Work at Karup Pharma?
Unlock and access historical data on people associated with Karup Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Karup Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Karup Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
